

SUPPORTING INFORMATION

Thermodynamic characteristics of cocrystal formation and melting points for rational design of pharmaceutical two-component systems

German L. Perlovich^{†,‡}

[†]Department of Physical Chemistry of Drugs, Krestov's Institute of Solution Chemistry, Russian Academy of Sciences, 153045 Akademicheskaya str. 1, Ivanovo, Russia;

[‡]Department of Computer-Aided Molecular Design, Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432, Chernogolovka, Russia;

CONTENT:	Page
Figure 1SI. The experimental data of the analyzed database in co-ordinates $T_{fus}(CC)$ versus $T_{fus}(API)$	S2
Figure 2SI. The experimental data of the analyzed database in co-ordinates $T_{fus}(CF)$ versus $T_{fus}(API)$	S3
Figure 3SI. The experimental data of the analyzed database in co-ordinates $T_{fus}(CC)$ versus $T_{fus}(CF)$	S4
Figure 4SI. The experimental data of the analyzed database in co-ordinates ($T_{fus}(API) - T_{fus}(CC)$) versus ($T_{fus}(API) - T_{fus}(CF)$)	S5
Figure 5SI. Correlation dependence (equation (1)) for potential coformers (CF) used at [Pyrazinamide+CF] cocrystals design	S6
Figure 6SI. Correlation dependence (equation (1)) for potential coformers (CF) used at [Succinic acid +CF] (2:1) cocrystals design	S7
Figure 7SI. Correlation dependence (equation (1)) for potential coformers (CF) used at [Tartaric acid +CF] (1:1) cocrystals design	S8
Figure 8SI. Experimental data of the melting points of 4,4'-bipyridine cocrystals versus HYBOT's physicochemical descriptors of the second components (coformers)	S9
Figure 9SI. Correlation dependence (equation (1)) for potential API used at [API + Imatinib mesylate] cocrystals design	S11

* To whom correspondence should be addressed:

Telephone: +7-4932-533784; Fax: +7-4932- 336237; E-mail glp@isc-ras.ru




Figure 1SI. The experimental data of the analyzed database in co-ordinates $T_{fus}(CC)$ versus $T_{fus}(API)$. Black line corresponds to bisector.




Figure 2SI. The experimental data of the analyzed database in co-ordinates $T_{fus}(CF)$ versus $T_{fus}(API)$. Red line corresponds to bisector.




Figure 3SI. The experimental data of the analyzed database in co-ordinates $T_{fus}(CC)$ versus $T_{fus}(CF)$. Red line corresponds to bisector.




Figure 4SI. The experimental data of the analyzed database in co-ordinates $(T_{fus}(API) - T_{fus}(CC))$ versus $(T_{fus}(API) - T_{fus}(CF))$. Red line corresponds to bisector.




Figure 5SI. Correlation dependence (equation (1)) for potential coformers (CF) used at [Pyrazinamide+CF] cocrystals design: 1 – glutaric acid (1:1); 2 – malonic acid (1:1); 3 – salicylic acid (1:1); 4 – 2-NH₂-benzoic acid (1:1); 5 – 4-NH₂- salicylic acid (1:1); 6 – Isoniazid (1:1); 7 – 3-NH₂-benzoic acid (1:1); 8 – succinic acid (1:1); 9 – 3-OH-benzoic acid (1:1); 10 – vanilic acid; 11 – succinic acid (2:1); 12 – 4-NH₂-benzoic acid (1:1); 13 – 2,5-OH-benzoic acid (1:1); 14 – 4-NO₂-benzamide (1:1); 15 – 3,4-OH-benzoic acid (1:1); 16 – 4-OH-benzoic acid (1:1); 17 – temozolomide (1:1); 18 – gallic acid (1:1); 19 – Hydrochlorothiazide (1:1); 20 – 1-OH-2-COOH-Naph (1:1).




Figure 6SI. Correlation dependence (equation (1)) for potential coformers (CF) used at [Succinic acid +CF] (2:1) cocrystals design: 1 – diphenylcyclopropenone; 2 – urea; 3 – fluoxetine hydrochloride; 4 – N'-(Propan-2-ylidene)isonicotinohydrazide; 5 – itraconazole (form I); 6 – itraconazole (form II); 7 – Pfizer 1; 8 – isonicotinic acid hydrazide; 9 – salbutamol; 10 – pyrazinamide; 11 – carbamazepine; 12 – nitazoxanide; 13 – AMG517; 14 – meloxicam (form I); 15 – meloxicam (form II).







Figure 7SI. Correlation dependence (equation (1)) for potential coformers (CF) used at [Tartaric acid +CF] (1:1) cocrystals design: 1 – [Tartaric acid (D)+gabapentin]; 2 – [Tartaric acid (L)+gabapentin]; 3 – [Tartaric acid (DL)+gabapentin]; 4 – [Tartaric acid (L)+carbamazepine]; 5 – [Tartaric acid (DL)+carbamazepine]; 6 – [Tartaric acid (L)+AMG517]; 7 – [Tartaric acid (L)+STL(+)]; 8 – [Tartaric acid (DL)+nevirapine]; 9 – [Tartaric acid (DL)+ciprofloxacin]; 10 – [Tartaric acid (L)+minoxidil].




a





c



d

Figure 8SI. Experimental data of the melting points of 4,4'-bipyridine cocrystals versus HYBOT's physicochemical descriptors of the second components (coformers) (α - molecular polarizability; ΣC_a - the sum of H-bond acceptor factors; ΣC_d - the sum of H-bond donor factors; ΣC_{ad} - the sum of H-bond donor and acceptor factors).




Figure 9SI. Correlation dependence (equation (1)) for potential API used at [API + Imatinib mesylate] cocrystals design.